Pharmacogenetic Prediction of Metoprolol Effectiveness
Status:
Terminated
Trial end date:
2017-08-23
Target enrollment:
Participant gender:
Summary
The investigators will prospectively follow a population of patients with uncontrolled high
blood pressure beginning metoprolol succinate therapy to determine the drug effect in an
observational clinical trial. The investigators will determine each individual's genotype for
both CYP2D6 and Adrenoceptor Beta 1 (ADRB1). Metabolomic markers will be identified to
determine if specific metabolites are associated with drug response. The investigators'
overall objective is to determine if genetics predicts metoprolol succinate response better
than clinical factors such as age, race, body mass index, dose, and medication co-ingestion.
Phase:
N/A
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
National Institute of General Medical Sciences (NIGMS)